临床肿瘤学杂志
臨床腫瘤學雜誌
림상종류학잡지
CHINESE CLINICAL ONCOLOGY
2014年
10期
925-928
,共4页
杜春霞%陈闪闪%刘潇衍%张弘纲
杜春霞%陳閃閃%劉瀟衍%張弘綱
두춘하%진섬섬%류소연%장홍강
重组人血管内皮抑素(恩度)%进展期胃癌%多西他赛%铂类%氟尿嘧啶类%一线化疗
重組人血管內皮抑素(恩度)%進展期胃癌%多西他賽%鉑類%氟尿嘧啶類%一線化療
중조인혈관내피억소(은도)%진전기위암%다서타새%박류%불뇨밀정류%일선화료
Rh-endostatin ( Endostar)%Advanced gastric cancer%Docetaxel%Platinates%Fluoropyrimidines%First-line chemotherapy
目的：探讨重组人血管内皮抑素（恩度）联合多西他赛、铂类和氟尿嘧啶类一线治疗进展期胃癌的疗效和安全性。方法回顾性分析2011年1月至2013年6月收治的进展期胃癌患者25例。17例接受多西他赛、奥沙利铂和氟尿嘧啶（ DOF）方案：多西他赛40mg/m2静滴，d1；奥沙利铂85mg/m2静滴，d2；氟尿嘧啶400mg/m2静滴，600mg/m2持续泵入22h，d2～d3，2周为1周期。8例接受多西他赛、顺铂和卡培他滨（DCX）方案：多西他赛40mg/m2静滴，d1；顺铂25mg/m2静滴，d2～d3；卡培他滨1000mg/m2口服，每天2次，d1～d8，2周为1周期。25例均接受恩度15mg/天静滴，d1～d10。根据RECIST 1．1版标准评价近期疗效，根据NCI CTC 3．0版标准评价毒副反应，同时随访无进展生存期（ PFS）和总生存期（ OS）。结果24例患者可评价疗效，其中获PR 10例，SD 6例，PD 8例；有效率为41．7％，疾病控制率为66．7％。毒副反应以消化道反应和骨髓抑制为主，主要3～4级毒副反应为中性粒细胞减少（6例），仅1例患者出现心脏毒性。中位随访时间14．6个月，中位PFS为8．0个月，中位OS 为11．0个月。结论恩度联合多西他赛、铂类和氟尿嘧啶类一线治疗进展期胃癌疗效确切，安全性良好，值得进一步研究。
目的：探討重組人血管內皮抑素（恩度）聯閤多西他賽、鉑類和氟尿嘧啶類一線治療進展期胃癌的療效和安全性。方法迴顧性分析2011年1月至2013年6月收治的進展期胃癌患者25例。17例接受多西他賽、奧沙利鉑和氟尿嘧啶（ DOF）方案：多西他賽40mg/m2靜滴，d1；奧沙利鉑85mg/m2靜滴，d2；氟尿嘧啶400mg/m2靜滴，600mg/m2持續泵入22h，d2～d3，2週為1週期。8例接受多西他賽、順鉑和卡培他濱（DCX）方案：多西他賽40mg/m2靜滴，d1；順鉑25mg/m2靜滴，d2～d3；卡培他濱1000mg/m2口服，每天2次，d1～d8，2週為1週期。25例均接受恩度15mg/天靜滴，d1～d10。根據RECIST 1．1版標準評價近期療效，根據NCI CTC 3．0版標準評價毒副反應，同時隨訪無進展生存期（ PFS）和總生存期（ OS）。結果24例患者可評價療效，其中穫PR 10例，SD 6例，PD 8例；有效率為41．7％，疾病控製率為66．7％。毒副反應以消化道反應和骨髓抑製為主，主要3～4級毒副反應為中性粒細胞減少（6例），僅1例患者齣現心髒毒性。中位隨訪時間14．6箇月，中位PFS為8．0箇月，中位OS 為11．0箇月。結論恩度聯閤多西他賽、鉑類和氟尿嘧啶類一線治療進展期胃癌療效確切，安全性良好，值得進一步研究。
목적：탐토중조인혈관내피억소（은도）연합다서타새、박류화불뇨밀정류일선치료진전기위암적료효화안전성。방법회고성분석2011년1월지2013년6월수치적진전기위암환자25례。17례접수다서타새、오사리박화불뇨밀정（ DOF）방안：다서타새40mg/m2정적，d1；오사리박85mg/m2정적，d2；불뇨밀정400mg/m2정적，600mg/m2지속빙입22h，d2～d3，2주위1주기。8례접수다서타새、순박화잡배타빈（DCX）방안：다서타새40mg/m2정적，d1；순박25mg/m2정적，d2～d3；잡배타빈1000mg/m2구복，매천2차，d1～d8，2주위1주기。25례균접수은도15mg/천정적，d1～d10。근거RECIST 1．1판표준평개근기료효，근거NCI CTC 3．0판표준평개독부반응，동시수방무진전생존기（ PFS）화총생존기（ OS）。결과24례환자가평개료효，기중획PR 10례，SD 6례，PD 8례；유효솔위41．7％，질병공제솔위66．7％。독부반응이소화도반응화골수억제위주，주요3～4급독부반응위중성립세포감소（6례），부1례환자출현심장독성。중위수방시간14．6개월，중위PFS위8．0개월，중위OS 위11．0개월。결론은도연합다서타새、박류화불뇨밀정류일선치료진전기위암료효학절，안전성량호，치득진일보연구。
Objective To investigate the efficacy and safety of rh-endostatin ( endostar) combined with docetaxel, platinates and fluoropyrimidines as first-line chemotherapy for advanced gastric cancer. Methods Twenty-five patients with advanced gastric cancer were enrolled into this study from Jan. 2011 to Jun. 2013. Seventeen patients received docetaxel, oxalipatin and flourouracil ( DOF) regimen:docetaxel 40mg/m2 iv, d1;oxaliplatin 85mg/m2 iv,d2;flourouracil 400mg/m2 iv, 600mg/m2 continuous iv 22h d2-d3 , with 2 weeks as a cycle. Eight patients received docetaxel, cisplatin and capecitabine ( DCX) regimen:docetaxel 40mg/m2 iv, d1;cisplatin 25mg/m2 iv, d2-d3;capetitabine 1000mg/m2 bid po, d1-d8 , with 2 weeks as a cycle. Endostar was administered 15mg/d iv, d1-d10 . The response rate was evaluated according to RECIST1. 1 criteria, and the toxicities were evaluated according to NCI CTC 3. 0 standard.Progression-free survival (PFS) and overall survival (OS) were also observed. Results Among the 24 evaluable cases, PR was observed in 10 patients, SD in 6 patients, and PD in 8 patients. The response rate was 41. 7%, and the disease control rate was 66. 7%. Digestive reaction and myelosuppression were the most common toxicities. Neutropenia( 6 cases) was the most frequent grade 3-4 toxicity. One patient experienced cardiac toxicity. The median follow-up was 14. 6 months, the median PFS was 8. 0 months, and the median OS was 11. 0 months. Conclusion Endostar combined with docetaxel, platinates and fluoropyrimidines is an effective and safe regimen as first-line chemotherapy for advanced gastric cancer. It is worthy of further large scale clinical trial.
